Through different preparation processes, DiQi Pharma uses new polymer materials to carry drugs to prepare long-acting injectable microspheres, long-acting implants, in-situ gel and other long-acting preparations, which can delay the absorption, distribution, metabolism and excretion of drugs in the body, reduce the number of times of administration, and has the characteristics of long-acting effect, safety and convenience.

Sustained and controlled release formulations include sustained-release formulations and controlled release formulations. DiQi Pharma, based on the characteristics of drugs and their absorption in the human body, uses techniques such as enteric coating, gastric retention, and skeletal drug release to purposefully control the sustained or controlled release of drugs to achieve long-lasting effects. Common sustained and controlled release preparations include coated pill cores, hydrophilic gel matrix tablets, stomach floating tablets, etc., which have the characteristics of improving patient compliance, reducing drug toxicity and side effects, and improving efficacy.

Polyethylene glycol is a water-soluble polymer that has been widely approved by the FDA for use as an additive in drugs and food. Modification with polyethylene glycol can increase the water solubility of protein drugs, reduce their immunogenicity, and improve their stability in vitro and in vivo.

Biodegradable materials are a new type of pharmaceutical excipient that have the advantages of good biocompatibility, non toxicity of materials and their degradation products, controllable degradation rate, adaptable physical properties, and good formability. They can be applied to sustained and controlled release drug delivery systems, medical devices, and beauty products.

We can be entrusted to develop drug research and development projects with high technological barriers. At present, we have provided technical services for the development of generic drug prescription processes and consistency evaluation for multiple well-known pharmaceutical companies. DiQi has initiated the development of over 100 generic drug products and has obtained approval from the US FDA for 4 of them; 19 generic drug consistency evaluation approvals have been obtained, and 6 are currently under CDE review; 18 BE experiments have passed the consistency evaluation, and the data is continuously increasing as the project progresses.